| 2/21/2025 | IG | Moody's raises AstraZeneca
|
| 8/22/2024 | IG | Fitch upgrades AstraZeneca
|
| 7/26/2024 | IG | Moody’s views AstraZeneca positively
|
| 7/26/2024 | IG | S&P boosts AstraZeneca
|
| 2/22/2024 | IG | New Issue: AstraZeneca prices $5 billion guaranteed notes over four parts
|
| 2/21/2024 | IG | AstraZeneca Finance plans to price fixed-rate notes in four parts
|
| 8/10/2023 | IG | Moody’s boosts AstraZeneca
|
| 3/1/2023 | IG | New Issue: AstraZeneca sells $2.25 billion of five-, seven-, 10-year notes
|
| 2/28/2023 | IG | AstraZeneca prepares to sell five-, seven-, 10-year notes
|
| 11/28/2022 | IG | S&P raises AstraZeneca
|
| 11/17/2022 | IG | Fitch raises AstraZeneca
|
| 11/16/2022 | IG | Moody's alters AstraZeneca trend to stable
|
| 12/13/2021 | IG | Fitch moves AstraZeneca view to positive
|
| 7/21/2021 | IG | S&P raises AstraZeneca
|
| 5/26/2021 | IG | New Issue: AstraZeneca details $7 billion of notes in six parts
|
| 5/25/2021 | IG | New Issue: AstraZeneca sells $7.25 billion of notes in six parts
|
| 5/25/2021 | IG | AstraZeneca sets price talk for $8 billion of notes in seven parts
|
| 5/24/2021 | IG | AstraZeneca intends to price seven tranches of notes
|
| 12/16/2020 | IG | S&P puts AstraZeneca on positive watch
|
| 12/15/2020 | IG | Fitch revises AstraZeneca view to stable
|
| 11/12/2020 | IG | S&P shifts AstraZeneca view to positive
|
| 10/6/2020 | IG | Fitch alters AstraZeneca view to positive
|
| 8/4/2020 | IG | New Issue: AstraZeneca gives details on $3 billion three-part sale of fixed-rate notes
|
| 8/3/2020 | IG | Market Commentary: Alphabet notes attract strong demand; AstraZeneca, Praxair, JetBlue, Textron, Kilroy price
|
| 8/3/2020 | IG | New Issue: AstraZeneca prices $3 billion of fixed-rate notes in three tranches
|
| 8/3/2020 | IG | Market Commentary: Morning Commentary: High-grade supply ramps up; Alphabet, AstraZeneca, Praxair, DTE eyed
|
| 8/3/2020 | IG | AstraZeneca to issue fixed-rate notes due 2026, 2030 and 2050
|
| 10/9/2019 | IG | Fitch affirms AstraZeneca
|
| 4/2/2019 | IG | Moody's lifts AstraZeneca view to stable
|
| 12/13/2018 | IG | Market Commentary: UnitedHealth sells $2.95 billion of notes; credit spreads firm; high-grade outflows rise
|
| 10/12/2018 | IG | Fitch trims AstraZeneca
|
| 8/27/2018 | IG | Market Commentary: Caterpillar reopens floaters; high-grade supply thins in front of holiday; bonds mixed
|
| 8/27/2018 | IG | Market Commentary: Morning Commentary: High-grade market action thins in front of holiday; primary quiet
|
| 8/22/2018 | IG | Market Commentary: Supply picks up; Bank of America, Nordea, Zions, Timken price notes; AstraZeneca steady
|
| 8/22/2018 | IG | Market Commentary: Morning Commentary: Timken to tap primary market; deal volume slows; AstraZeneca busy
|
| 8/17/2018 | IG | Market Commentary: High-grade volume subsides after solid week; United Technologies firms; McDonald’s mixed
|
| 8/17/2018 | IG | Market Commentary: Morning Commentary: Primary quiet after strong week; high-grade inflows mostly decline
|
| 8/16/2018 | IG | Market Commentary: AT&T, Huntington Bank, Protective Life, Willis Lease tap primary; AstraZeneca notes improve
|
| 8/15/2018 | IG | Market Commentary: Morning Commentary: Supply slows; South Carolina Electric offers bonds; Fluor eyed
|
| 8/15/2018 | IG | New Issue: AstraZeneca details $3 billion four-part fixed-, floating-rate notes
|
| 8/14/2018 | IG | Market Commentary: AstraZeneca, Elanco, Roper, Apache, AerCap price; United Technologies, McDonald’s firm
|
| 8/14/2018 | IG | New Issue: AstraZeneca prices $3 billion of fixed- and floating-rate notes
|
| 8/14/2018 | IG | Market Commentary: Morning Commentary: Strong supply on tap; AstraZeneca, Apache, Roper, IBRD eye deals
|
| 8/14/2018 | IG | AstraZeneca to issue fixed-rate, floating-rate notes in four parts
|
| 8/1/2017 | IG | Fitch downgrades AstraZeneca to A-
|
| 7/28/2017 | IG | Moody’s changes AstraZeneca to negative
|
| 7/28/2017 | IG | S&P downgrades AstraZeneca, debt to BBB+
|
| 6/5/2017 | IG | Market Commentary: AstraZeneca, Atmos Energy, ConEd, Dr Pepper Snapple tap primary market; credit spreads steady
|
| 6/5/2017 | IG | New Issue: AstraZeneca sells $2 billion three-part offering of fixed- and floating-rate notes
|
| 6/5/2017 | IG | Market Commentary: Morning Commentary: High-grade deal pipeline fills; AstraZeneca, Autodesk, Dr. Pepper to price
|
| 6/5/2017 | IG | AstraZeneca to sell three tranches of fixed-, floating-rate notes
|
| 4/19/2017 | IG | S&P revises AstraZeneca to negative
|
| 4/4/2016 | IG | Market Commentary: Primary sees $12 billion of issuance from Target, BMW, others; Pfizer, AT&T tighten modestly
|
| 3/3/2016 | IG | Market Commentary: ConocoPhillips, Stryker price ahead of jobs data; AstraZeneca gains; Procter & Gamble eases
|
| 1/21/2016 | IG | Market Commentary: World Bank, Cades bring new issues; Shell bonds tighten as oil prices rebound; Barclays firms
|
| 1/12/2016 | IG | Market Commentary: Financials storm investment-grade primary; MetLife notes flat; Pfizer, AstraZeneca firm
|
| 12/18/2015 | IG | Moody’s downgrades AstraZeneca to A3
|
| 12/18/2015 | IG | S&P downgrades AstraZeneca to A-
|
| 12/18/2015 | IG | Fitch cuts AstraZeneca, debt to A
|
| 12/11/2015 | IG | Fitch changes AstraZeneca to negative
|
| 11/10/2015 | IG | Market Commentary: AstraZeneca does $6 billion deal; Canadian Railway, Burlington Northern trade mostly flat
|
| 11/10/2015 | IG | New Issue: AstraZeneca prices $6 billion of notes in five tranches for ZS Pharma acquisition
|
| 11/10/2015 | IG | S&P downgrades AstraZeneca to A
|
| 11/10/2015 | IG | AstraZeneca sets talk for benchmark five-tranche offering of notes; pricing Tuesday
|
| 11/9/2015 | IG | Moody’s revises AstraZeneca to negative
|
| 5/1/2015 | IG | S&P drops AstraZeneca to A+
|
| 11/21/2014 | IG | Fitch lowers AstraZeneca
|
| 11/22/2013 | IG | Fitch: AstraZeneca negative
|
| 4/11/2013 | IG | Moody's lowers AstraZeneca
|
| 4/8/2013 | IG | S&P cuts AstraZeneca view to negative
|
| 9/12/2012 | IG | Market Commentary: Midday Commentary: Market firms slightly, feels 'stalled' overall; AstraZeneca tightens
|
| 9/12/2012 | IG | New Issue: AstraZeneca gives terms of $2 billion sale of bonds due 2019, 2042
|
| 9/11/2012 | IG | AstraZeneca announces talk for note sale in seven-, 30-year tranches
|
| 9/11/2012 | IG | New Issue: AstraZeneca sells $2 billion of seven-, 30-year bonds
|
| 9/11/2012 | IG | Market Commentary: AstraZeneca returns to market with $2 billion deal, joins RBS, News America, Computer Sciences
|
| 7/5/2012 | IG | Moody's: AstraZeneca negative
|
| 10/11/2011 | IG | Fitch affirms AstraZeneca
|
| 12/21/2010 | IG | AstraZeneca files automatic shelf registration for debt securities
|
| 12/3/2010 | IG | Fitch affirms AstraZeneca
|
| 2/18/2009 | IG | Market Commentary: Roche sells mega deal, Canadian National Rail, Goodrich also price; DuPont new bonds widen
|
| 9/5/2008 | IG | Fitch affirms AstraZeneca
|
| 4/16/2008 | IG | Market Commentary: GE Capital prices massive deal on decent open, bank earnings; Martin Marietta also issues
|
| 9/13/2007 | IG | Market Commentary: Enel prices $3.5 billion of notes, Florida Power, J.P. Morgan also brave market on quiet day
|
| 9/6/2007 | IG | Market Commentary: Summer lull is over with more than $8 billion in new investment grade issues pricing
|
| 9/5/2007 | IG | New Issue: AstraZeneca prices $6.9 billion of notes in four tranches
|
| 9/5/2007 | IG | Market Commentary: Flood hits investment grade market with nearly $13 billion in new issues
|
| 9/4/2007 | IG | AstraZeneca to price notes in three tranches
|
| 8/31/2007 | IG | AstraZeneca files debt securities automatic shelf registration
|
